Researchers at St Jude Children's Research Hospital used high throughput screening (HTS) to identify SJ3149, a molecular glue degrader. This small molecule demonstrated efficacy across a range of cancer types.

We discuss working on PROTACs, targeting novel E3 ubiquitin ligases, and Dr Galdeano's spin out Oniria Therapeutics.

Delving into PhoreMost's role in targeted protein degradation, the innovation behind the SITESEEKER platform, and the challenges and breakthroughs in the dynamic field of drug discovery.

Discussing the challenges and strategies in targeted protein degradation (TPD), a promising therapeutic modality with the potential to drug difficult or "undruggable" protein targets.

Yusuke will be giving a keynote presentation at Discovery Europe 2023 titled 'Targeted Protein Degradation And Addressing Undruggable Targets'.

Felix will deliver his presentation 'Clues for Molecular Glues' at Drug Discovery Europe 2023.

Using the body's mechanisms to degrade proteins not amenable to traditional small molecule approaches, offering the potential to "drug the undruggable" and permanently destroy target proteins.

Thomas Hayhow, Associate Principal Scientist at AstraZeneca presents his company’s efforts in delivering PROTACs orally.

A Senior Director at AstraZeneca takes us through how the company synthesises and validates novel PROTACs.

Oxford Global’s protein degradation panel discussion brought together leading experts in the field to talk about bringing PROTACs to clinical trial endpoints.

During Discovery Week 2021, Ian Churcher (Chief Scientific Officer at Amphista Therapeutics Limited) gave a fascinating presentation on recent advancements and novel approaches in protein degradation. This article provides a condensed overview of the key topics covered.

Progress in protein degradation has accelerated in the past few years, and 2021 saw several breakthroughs. Efforts to target STAT3, however, have proven to be especially challenging.